Immunovaccine Signs License Agreement With Pfizer Animal Health

License agreement signed between Pfizer Animal Health and Immunovaccine.

Immunovaccine Inc. of Halifax, Nova Scotia, recently licensed its patented vaccine delivery technology to Pfizer Animal Health. The New York-based company plans to develop enhanced cattle vaccines incorporating the technology.

Specific terms of the exclusive, worldwide license agreement were not disclosed. However, Immunovaccine reported that it will receive upfront signing fees in addition to subsequent milestone payments and royalties on any Immunovaccine-delivered vaccines developed by Pfizer Animal Health.

The strength of Immunovaccine’s platform lies in its ability to reduce the number of required doses and to significantly enhance antibody onset and duration, according to the company.

“We see global demand growing among beef and dairy producers for new vaccines that can be safely and easily administered,” said Juan Ramon Alaix, president of Pfizer Animal Health. “Pfizer looks forward to developing cattle vaccines incorporating Immunovaccine technology that will contribute to meeting this demand.”

Pfizer Animal Health reported that it is also licensing other Immunovaccine technology for the development of particular livestock vaccines.

<HOME>

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.